在质母细胞瘤中,第一类小分子瘤基因AVIL的抑制剂
Zhongqiu Xie1, Sophia Xie1, Hui Li1,2
1Department of Pathology, School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
DNA and cell biology
|March 10, 2026
概括
研究人员确定了活性调节蛋白AVIL作为质母细胞瘤多种 (GBM) 的关键驱动因素. 用一种新型化合物向AVIL显示出治疗这种侵略性脑癌的重大前景.
科学领域:
- 神经瘤学神经瘤学
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 多形质母细胞瘤 (GBM) 是一种具有不良预后的侵袭性原发性脑瘤.
- 目前的疗法提供了有限的生存益处,需要新的治疗点.
- 调节行动蛋白AVIL的蛋白质被研究其在GBM病原发生中的作用.
研究的目的:
- 研究AVIL在多形质母细胞瘤 (GBM) 发育和进展中的作用.
- 确定和评估一种针对GBM中的AVIL的新型治疗策略.
主要方法:
- 对GBM数据集的基因组和转录组分析 (REMBRANDT,TCGA,CGGA).
- 功能性研究包括基因沉默,过度表达和*in vitro*/*in vivo*异种移植模型.
- 小分子查以确定AVIL特异性抑制剂;确定化合物的临床前疗效测试.
主要成果:
- 在GBM中出现反复的AVIL放大和一致的过度表达,跨分子亚型和质瘤干细胞 (GSCs).
- 艾维尔对于质瘤的产生至关重要,它通过actin细胞骨架重塑和FOXM1-LIN28B通路激活驱动细胞质瘤的增殖,迁移和转变.
- 选择性AVIL抑制剂 (化合物A) 显示出强大的GBM细胞生长抑制,在临床前模型中的抗瘤疗效,以及有利的药理动力学特性.
结论:
- 艾维尔是多种质母细胞瘤中关键的瘤驱动因素.
- 准AVIL代表了对GBM的一个有前途的治疗策略.
- 一个一流的AVIL抑制剂显示出对精确神经瘤学的显著翻译潜力.
更多相关视频
相关概念视频
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
01:20The Retinoblastoma Gene
4.9K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K
02:49Cancer Therapies
10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
01:22PI3K/mTOR/AKT Signaling Pathway
6.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.1K